EUCTR2017-002758-35-FR进行中（未招募）1 期
Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers - AURA
Insitut Jules Bordet0 个研究点目标入组 183 人开始时间: 2018年4月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 183
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •2) Must have histologically confirmed muscle invasive urothelial
- •carcinoma (transitional cell carcinoma) or urothelial carcinoma with
- •mixed histology of the bladder, renal pelvis or ureters. Stage permitted:
- •T2, T3 or T4a. T stage is based on the standard of care transurethral
- •resection of the bladder tumour (TURBT) sample
- •3) Patients may have nodal disease (Nx, N0, N1 or N2) at imagery but
- •there must be no evidence of distant metastases (M0)
- •4) Performance status 0 or 1 on the Eastern Cooperative Oncology Group
- •5) Be a medically appropriate candidate for surgery as determined by an
- •attending urologist
- •6) Adequate bone marrow function as defined below
- •- Absolute neutrophil count =1500/µL or 1.5x109/L
- •- Hemoglobin = 9 g/dL
- •- Platelets =100,000/µL or 100x10 9/L
- •7) Adequate liver function as defined below
- •- Serum total bilirubin = 1.5 x ULN. In case of known
- •Gilbert's syndrome < 3xUNL is allowed
- •- AST (SGOT)/ALT (SGPT) = 2.5 x ULN
- •8) Serum pregnancy test (for subjects of childbearing potential)
- •negative within 7 days prior to study treatment administration.
- •9) Women of childbearing potential must agree to use one highly
- •effective method of contraception prior study entry, during the course of
- •the study and up to 6 months after the last administration of study
- •treatment. Men with childbearing potential partner must agree to use
- •condom during the course of this study and up to 6 months after the last
- •administration of the study treatment.
- •10) Completion of all necessary screening procedures within 28 days
- •prior to treatment.
- •11) Availability of biological material for screening and/or translational
- •research activities
- •12) Signed Informed Consent form (ICF) obtained prior to any study
- •related procedure.
- •Cisplatin-eligible cohort specific criteria:
- •13) Glomerular filtration rate (GFR) or Creatinine
- •Clearance= 60 mL/min according to the Cockcroft-
- •Gault formula (or local institutional standard method) and
- •14) Peripheral neuropathy = grade 1 and
- •15) Hearing impaired = grade 1 and
- •16) Adequate cardiac function (Left Ventricular Ejection
- •Fraction LVEF = 55%) by MUGA (Multiple-Gated
- •Acquisition) scan or echocardiography
- •Cisplatin ineligible cohort specific criteria (if any of the following
- •17) Glomerular filtration rate (GFR) or Creatinine
- •Clearance = 30mL/min according to the CockcroftGault formula (or local
- •institutional standard method) or
- •18) Peripheral neuropathy = grade 2 or
- •19) Hearing impaired = grade 2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- 另有 3 项未显示
排除标准
- •Subjects meeting one of the following criteria are not eligible for this study:
- •1) Metastatic disease (M1)
- •2) Has had prior systemic chemotherapy, targeted small molecule therapy, or radiation therapy for urothelial carcinoma
- •3) Prior treatment with drug specifically targeting T-cell co-stimulation or checkpoint pathways
- •4) Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses = 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
- •5) Has an active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
- •6) Has had a prior organ transplantation including allogenic stem-cell transplantation.
- •7) Has an active infection requiring systemic therapy
- •8) Has a known history of Human Immunodeficiency Virus (HIV) or known acquired immunodeficiency syndrome.
- •9) Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA is detected)
- •10) Has received vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines such as influenza vaccine.
- •11) Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 28 days prior to study registration
- •12) History of prior invasive malignancy within 2 years (exception of adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localised prostate cancer or ductal carcinoma in situ)
- •13) Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade = 3)
- •14) Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrolment), myocardial infarction (< 6 months prior to enrolment), unstable angina, congestive heart failure (= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.”
- •15) Pregnant and/or lactating women.
- •16) Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator’s opinion, may interfere with completion of the study.
- •17) Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade >1); however, alopecia, sensory neuropathy Grade =2, or other Grade =2 not constituting a safety risk based on investigator’s judgment are acceptable.
- •18) Other severe acute chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behaviour; or laboratory abnormalities that may increase the risk associated with the study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
进行中（未招募）
1 期
Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancersrothelial CarcinomaMedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 100000004864EUCTR2017-002758-35-BEInsitut Jules Bordet183
已完成
2 期
Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)Non-metastatic Muscle Invasive Bladder CancerNCT03674424Jules Bordet Institute137
已完成
2 期
Adjuvant Treatment with nivolumab in the Prevention of recurrence after curative treatment of Hepatocellular Carcinoma(NIVOLVE)Hepatocellular CarcinomaJPRN-UMIN000026648Kindai University Faculty of Medicine Department of Gastroenterology and Hepatology55
进行中（未招募）
1 期
Avelumab in combination with Axitinib in patients with advanced Thymic tumoursHistologically confirmed advanced Thymoma B3 or Thymic carcinoma inoperable (Masaoka Stage IIIb or IV).MedDRA version: 21.1Level: PTClassification code 10055108Term: Thymic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004048-38-ITISTITUTO EUROPEO DI ONCOLOGIA33
进行中（未招募）
1 期
A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinomaThoracic esophageal cancerJPRN-jRCT2031180172Kato Ken36